# An Open Label, Phase 1b, Ascending Dose Study of DM199

> **NCT02868996** · PHASE1 · COMPLETED · sponsor: **DiaMedica Therapeutics Inc** · enrollment: 36 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Recombinant human tissue kallikrein

## Key facts

- **NCT ID:** NCT02868996
- **Lead sponsor:** DiaMedica Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868996, "An Open Label, Phase 1b, Ascending Dose Study of DM199". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02868996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*